一种新型ROR1/PI3Kα/BRD4多位抑制剂对抗NSCLC的疗效
Ting Zhong1, Ji Yun Lee2, Qing Li1
1State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Natural Products Research Center of Guizhou Province, Guiyang 550014, China.
Bioorganic & medicinal chemistry
|November 15, 2025
概括
研究人员开发了BIQO-9,这是一种针对非小细胞肺癌 (NSCLC) 的新型多位抑制剂. 这种化合物向ROR1,PI3Kα和BRD4,显示出卓越的抗瘤活性,并增强Gefitinib在NSCLC治疗中的疗效.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 受体氨酸激酶类孤儿受体1 (ROR1),酸丁醇3-激酶α (PI3Kα) 和含原蛋白4 (BRD4) 对于非小细胞肺癌 (NSCLC) 的进展至关重要.
- 像Gefitinib这样的现有治疗方法由于耐药性和副作用而存在局限性.
- 目前没有任何抑制剂同时向ROR1,PI3Kα和BRD4.
研究的目的:
- 发现和描述一种新的NSCLC多向抑制剂.
- 评估新型化合物BIQO-9.0的抗瘤活性和分子机制.
- 评估BIQO-9与Gefitinib结合的协同效应.
主要方法:
- 从化合物9a中开发BIQO-9的结构-活性关系研究.
- 对NSCLC细胞系进行细胞毒性评估的MTT试验 (A549,H1975).
- 激酶活性测定,激酶分析,生物素拉下,和CETSA来识别目标.
- 流动细胞计和西布洛特分析,以调查细胞效应和信号通路.
- 使用老鼠异种移植模型进行体内研究.
主要成果:
- BIQO-9表现出强大的抗NSCLC活性,IC50值明显低于化合物9a.
- BIQO-9有效抑制PI3Kα,并被确定为ROR1和BRD4.4的直接抑制剂.
- 通过抑制ROR1,PI3K和BRD4下游通路,BIQO-9诱导了A549细胞的G2阶段细胞周期停止和细胞亡.
- 与BIQO-9和Gefitinib的联合治疗在体外和体内都显示出增强的疗效.
结论:
- BIQO-9是首个同时向ROR1,PI3Kα和BRD4的已识别的抑制剂,对NSCLC显示出显著的治疗潜力.
- BIQO-9与Gefitinib的组合为NSCLC治疗提供了一个有前途的新疗法策略.
关键词:
细胞灭亡 (apoptosis) 是一种死亡的过程.在BIQO-9中,我们可以看到BIQO-9的情况.G(2) 停机阶段停机阶段盖菲提尼布 (Gefitinib) 是一种药物.非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.这是一种ROR1/PI3Kα/BRD4多位抑制剂.更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
14.3K
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.5K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K